All

New agreement paves way for development of first African-owned COVID-19 vaccine.

Press Release Univercells acquires Synhelix, entering into synthetic biology and the race to next-generation DNA synthesis January 13, 2022 Univercells S.A. (Univercells) today announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable and automated DNA synthesis technology resulting in one-step generation of long DNA fragments, at…

Press Release Quantoom Biosciences granted $13.9 million (€12.4 million), to support the development of its novel MRNA manufacturing platform for vaccines and therapeutics December 20, 2021 The objective is to make RNA therapeutics accessible to global patient populations. Makes large-scale decentralized RNA production economically viable. Quantoom Biosciences S.A. (“Quantoom”), a biotech with the mission to…

Press Release Etherna Immunotherapies and Quantoom Biosciences announce a strategic collaboration for the development of a novel RNA production system June 29, 2021 The objective is to make RNA therapeutics accessible to global patient populations. Makes large scale decentralized RNA production economically viable. eTheRNA immunotherapies NV (‘eTheRNA’), a clinical-stage company developing mRNA-based immunotherapies with in-house…

Press Release Introducing Quantoom Biosciences, a Univercells company, with the mission to improve access to essential medicines and autonomy in bioproduction through innovation June 7, 2021 Univercells S.A. introduces its latest affiliate, Quantoom Biosciences S.A., a biotech with the mission to improve access to essential medicines and autonomy in bioproduction through innovation. Quantoom Biosciences develops…